Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CTSC | P53634 | 5/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538881 | 0.91 | CTSC (0.49) | KMT2ANPSR1CTSCDPP4LNPEP | |
| SCHEMBL27538884 | 0.91 | CTSC (0.49) | KMT2ANPSR1CTSCDPP4LNPEP | |
| SCHEMBL27515492 | 0.90 | CTSC (0.48) | KMT2ANPSR1CTSCDPP4LNPEP | |
| SCHEMBL27515493 | 0.90 | CTSC (0.48) | KMT2ANPSR1CTSCDPP4LNPEP | |
| SCHEMBL21883049 | 0.90 | NOS2 (0.51) | CTSCDPP4CTSKKCNH2 | |
| SCHEMBL21883031 | 0.90 | CTSC (0.50) | CTSCDPP4CTSKKCNH2KDM4E | |
| SCHEMBL26510556 | 0.89 | CTSC (0.63) | CTSCDPP4NLRP3TSHR | |
| SCHEMBL18374167 | 0.89 | TERT (0.48) | KMT2ANPSR1CTSCDPP4LNPEP | |
| SCHEMBL27516198 | 0.89 | CTSC (0.48) | KMT2ANPSR1CTSCDPP4CTSK | |
| SCHEMBL27516197 | 0.89 | CTSC (0.48) | KMT2ANPSR1CTSCDPP4CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331045-A | Method for preparing peptide | 苏尔福工具股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-111770930-B | Method for preparing peptide | 苏尔福工具股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-11976094-B2 | Method for preparing peptides | SULFOTOOLS GMBH (DE) | 2024-05-07 | — | — | US | disclosed |
| EP-3988561-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| EP-3988561-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| US-20220220151-A1 | METHOD FOR PREPARING PEPTIDES | SULFOTOOLS GMBH (DE) | 2022-07-14 | — | — | US | disclosed |
| US-11319340-B2 | Method for preparing peptides | SULFOTOOLS GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| EP-3988561-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2022-04-27 | — | — | EP | disclosed |
| EP-3988561-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2022-04-27 | — | — | EP | disclosed |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | XWPharma Ltd. (KY) | 2022-04-26 | — | — | US | disclosed |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | XWPharma Ltd. (KY) | 2022-04-26 | — | — | US | disclosed |
| EP-3679051-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2021-12-29 | — | — | EP | disclosed |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | XWPharma Ltd. (KY) | 2021-03-04 | — | — | US | disclosed |
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | XW LABORATORIES INC. (KY) | 2021-01-12 | — | — | US | disclosed |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2020-06-25 | — | — | US | disclosed |
| WO-2019041361-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XW LABORATORIES, INC. (CN) | 2019-03-07 | — | — | WO | disclosed |
| EP-1001972-A1 | SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006431-A1 | SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976094-B2 | Method for preparing peptides | VIP, DNPEP, PEPD | KMT2A 4411/4885NPSR1 308/4885CTSC 59/4885 |
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | KMT2A 4439/4885NPSR1 376/4885CTSC 2754/4885 |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | GSR, TXNRD2, GPX1 | KMT2A 4439/4885NPSR1 376/4885CTSC 2754/4885 |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | GPX1, SOD1, GPX4 | KMT2A 4630/4885NPSR1 191/4885CTSC 2493/4885 |
| US-11319340-B2 | Method for preparing peptides | VIP, DNPEP, PEPD | KMT2A 3424/4885NPSR1 222/4885CTSC 46/4885 |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | KMT2A 4439/4885NPSR1 376/4885CTSC 2754/4885 |
| US-20220220151-A1 | METHOD FOR PREPARING PEPTIDES | VIP, DNPEP, PEPD | KMT2A 4411/4885NPSR1 308/4885CTSC 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.